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Introduction:  Etomidate  causes  pain  when  injected  intravenously.  In  this  study  we  sought  to
determine if  pretreatment  by  ondansetron  reduces  the  pain  on  injection  of  etomidate.
Methods: In  this  randomized,  double  blinded,  placebo-controlled  clinical  trial,  20  patients  of
both  sexes  aged  between  18  and  50  years  of  American  Society  of  Anesthesiologists  (ASA)  physical
status  class  I  or  II,  whom  were  candidates  for  various  elective  surgical  procedures  and  need  more
than  one  intravenous  access  were  enrolled  in  the  study.  On  arrival  to  the  operating  room  two
22  gauge  cannulas  were  inserted  into  veins  on  the  dorsum  of  both  hands.  Following  the  infusion
of  100  mL  normal  saline  into  both  intravenous  lines,  using  an  elastic  band,  venous  drainage  of
hands  was  occluded  at  midarm.  The  patients  were  administered  8  mg  (2  mL)  of  ondansetron
into one  hand  and  2  mL  of  0.9%  saline  into  the  other  hand  at  the  same  time.  The  elastic  band
was  removed  after  1  min  and  2  mg  (1  mL)  of  etomidate  was  administered  at  the  same  rate
simultaneously  into  intravenous  lines.  The  patients  were  asked  to  give  a  score  of  pain  based  on
a  verbal  analog  scale  (VAS)  to  each  hand.
Results:  A  total  number  of  20  patients  were  studied  (male  =  55%,  female  =  45%).  The  mean  age
of the  participants  was  37.5  ±  13.1  years  old  and  the  mean  weight  was  67.7  ±  7.3  kg.  The  mean
VAS  for  injection  pain  of  etomidate  after  pre-administration  of  intravenous  ondansetron  was
1.5  ±  1.2  which  was  lower  compared  to  pre-administration  of  placebo  (3.2  ±  2.8,  p  <  0.05).
Conclusion:  This  study  illustrates  that  pre-treatment  with  intravenous  ondansetron  signiﬁcantly
reduces the  pain  on  injection  of  etomidate.
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arious  agents  have  been  used  for  intravenous  induction  of
nesthesia, yet  some  of  the  side  effects  induced  by  different
rugs limit  their  use.1
Etomidate  is  one  of  the  popular  intravenous  anesthetic
gents, which  can  be  administered  during  induction  of
eneral anesthesia  or  sedation  for  short  procedure.1 Pro-
ylene glycol  formulated  etomidate  may  damage  vascular
ndothelium and  produce  pain.2 Etomidate  is  famous  for
ts cardiovascular  stability,  nevertheless  injection  pain  and
ostoperative vomiting  are  two  unpleasant  adverse  effects
ttributable to  this  drug.3
The  broad  distribution  of  ﬁve  hydroxytryptamine  (5-HT3)
eceptors in  human  body  has  provided  the  basis  for  investiga-
ion of  ondansetron,  as  a  selective  serotonin  5-HT3  receptor
ntagonist in  novel  applications,  although  the  results  have
ot always  been  consistent.4,5
The  primary  outcome  of  the  present  study  was  to  deter-
ine the  effect  of  ondansetron  on  prevention  of  injection
ain caused  by  etomidate  during  induction  of  anesthesia.
ethods
thics
his  trial  was  reviewed  and  approved  by  the  Institute  of  Eth-
cal  Committee  and  Iranian  Registry  of  Clinical  Trials  (IRCT
D: IRCT201106125140N4).
The study  protocol  was  approved  by  the  Institutional
thics committee  of  Tehran  University  of  Medical  Sci-
nces. Ethical  approval  for  this  study  (Ethical  Committee
◦ 91/2/201/22501)  was  provided  by  the  Ethical  Committee
f Tehran  University  of  Medical  Sciences  (Chairperson  Prof.
h. Akhondzade)  on  15  January  2013.  An  informed  written
onsent was  obtained  from  all  the  participants.
atient’s  population
n  this  randomized,  double  blinded,  placebo-controlled  clin-
cal trial,  20  patients  of  both  sexes  aged  between  18  and  50
ears of  American  Society  of  Anesthesiologists  (ASA)  physical
tatus class  I  or  II,  who  were  candidates  for  various  elec-
ive surgical  procedures  requiring  more  than  one  intravenous
ccess lines  were  enrolled  in  the  study.
Exclusion  criteria  consisted  of  patients  with  a  history  of
hrombophlebitis or  vascular  disease,  chronic  pain,  diabetes
ellitus, history  of  tumors  or  burns  in  either  hands,  his-
ory of  addiction  or  any  contraindications  to  injection  of
ndansetron or  etomidate.
In the  preoperative  visit  the  night  before  surgery  all  the
atients were  thoroughly  explained  the  visual  analog  scale
VAS) for  pain  (0  =  no  pain,  10  =  most  severe  pain).  No  pre-
edications were  administered.
nterventionn  arrival  to  the  operating  room,  all  patients  were  moni-
ored with  an  electrocardiogram  (ECG),  noninvasive  blood
ressure and  pulse  oximetry.  All  the  required  drugs  were
t
r
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repared  into  opaque  syringes  by  an  anesthetist  who  was
ot involved  in  either  the  administration  of  drugs  to  patients
r the  patients’  assessment;  thus,  both  the  anesthesiologist
nd the  patients  were  blinded  to  patients  groups.
Two  22  gauge  cannulas  were  inserted  into  the  veins  on  the
orsum of  both  hands.  One  hundred  millimeters  of  saline
as administered  over  10  min  from  each  of  the  cannulas.
sing an  elastic  band  as  a  tourniquet,  venous  drainage  of
oth hands  was  occluded  midarm.  Eight  milligrams  (2  mL)
f ondansetron  was  administered  from  one  hand  and  2  mL
f 0.9%  saline  from  the  other  hand  at  the  same  time.  The
lastic band  was  removed  after  1  min  and  2  mg  (1  mL)  of  eto-
idate was  administered  at  the  same  rate  simultaneously
t both  hands.  The  patients  were  asked  to  give  a  score
rom 0  to  10  (0  =  no  pain  and  10  =  most  severe  pain)  to  each
and. Adverse  effects  were  also  recorded.  The  choice  for
he technique  used  for  induction  of  anesthesia  was  left
or the  anesthesiologist  to  make  based  on  every  individual.
ndotracheal intubation  was  facilitated  with  0.5  mg  kg−1
tracurium.  After  tracheal  intubation,  anesthesia  was  main-
ained by  isoﬂuran  and  N2O  (50%);  0.1  mg  kg−1 atracurium
nd 1  g  kg−1. Fentanyl  were  administered  half  hourly.  Ven-
ilation was  adjusted  to  maintain  normocapnia  (end-tidal
arbon dioxide  partial  pressure  4.7--5.3  kPa).
tatistics
t  was  estimated  that  a  sample  size  of  20  patients  (40  hands)
ould be  sufﬁcient  to  detect  a  3  score  difference  in  pain  on
njection of  etomidate,  estimating  a  SD  of  3.5,  power  of  95%
nd signiﬁcant  level  of  0.05.
Statistical  analysis  of  the  results  was  performed  using
PSS for  windows,  release  17.5  (SPSS  Inc.).  The  intensity  of
ain was  analyzed  by  two  sample  t-test.  p-Value  <0.05  was
onsidered statistically  signiﬁcant.  The  power  of  study  was
onsidered 20%.
esults
hree  patients  were  deeply  sedated  after  injection  of  etomi-
ate and  unable  to  answer  any  questions.  We  replaced  these
hree patients  with  new  cases.  A  total  number  of  20  patients
ere enrolled  in  the  study  (male  =  55%,  female  =  45%).  The
ean age  of  the  participants  was  37.5  ±  13.1  years  and  the
ean weight  was  67.7  ±  7.3  kg.  The  mean  VAS  for  injection
ain of  etomidate  after  pre-administration  of  intravenous
ndansetron was  1.5  ±  1.2  which  was  lower  compared
o pre-administration  of  placebo  (3.2  ±  2.8,  p  <  0.05).  Six
atients developed  urticaria  following  administration  of
ndansetron and  before  etomidate  administration.  No  life
hreatening or  major  complications  were  observed.
iscussion
n  this  study  the  effect  of  intravenous  ondansetron  on  injec-
ion pain  of  etomidate  was  evaluated.  It  was  observed  that
dministration of  ondansetron  prior  to  etomidate  reduces
he injection  pain  signiﬁcantly.
Ondansetron  has  been  shown  to  bind  to  opioid  -
eceptors in  humans  and  possess  agonist  activity.6 Five





















1Ondansetron  and  pain  on  injection  of  etomidate  
pathways.  Five  hydroxytryptamine  receptors  play  a  prono-
ciceptive role  and  mediate  descending  excitatory  controls
that allow  spinal  neurons  to  fully  code  peripheral  stimuli.
Ondansetron decreases  chronic  benign  neuropathic  pain,
this effect  seems  to  be  produced  by  an  action  on  the  neu-
rons in  the  spinal  cord  that  code  and  transmit  peripheral
nociceptive stimuli.7
Five  hydroxytryptamine  receptors  are  also  a  target  for
local anesthetics.  The  ability  of  ondansetron  to  block  sodium
channels and  5-HT3  receptor  has  put  forward  the  hypoth-
esis that  ondansetron  possesses  antinociceptive  properties
probably in  a  similar  way  to  local  anesthetics.  Although
local anesthetics  contain  hydrophilic  and  hydrophobic  struc-
tures  separated  by  an  intermediate  amide  or  ester  linkage,
a structure  which  ondansetron  does  not  have.8,9
Reducing  injection  pain  of  intravenous  anesthetics  has
been the  subject  of  various  studies.  Many  drugs  have  been
previously used  to  attenuate  injection  pain  of  propofol
and rocuronium.  Lidocaine  or  fentanyl  with  local  anes-
thetic and  sedative  properties  are  the  most  commonly
used drugs.10--13 When  compared  to  tramadol,  ondansetron
was equally  effective  in  preventing  pain  of  propofol  injec-
tion, holding  the  analgesic  properties  of  ondasetron,  and
was superior  due  to  prevention  of  post  operative  nau-
sea and  vomiting.14 Metoclopramide,  and  ﬂurbiprofenaxetil,
granisetron and  ketamine  effect  on  attenuating  pain  on
injection have  all  been  previously  studied.15--19
Quantiﬁcation  of  pain  is  a  great  challenge  to  researchers.
Visual analog  scale  is  one  of  the  most  popular  methods
used for  pain  assessment,  but  it  is  subjective  and  is  difﬁ-
cult to  evaluate  quantitatively  or  statistically.  Reported  pain
levels by  individuals  using  VAS  are  based  on  every  individ-
uals pain  threshold,  which  is  unknown,  making  the  whole
results defective  when  compared  between  individuals.  Not
only a  different  deﬁnition  of  pain  exists  in  different  cul-
tures around  the  world  but  also  individual  variability  exists
in perception  of  pain.  Even  every  individual’s  pain  threshold
may change  based  on  the  underlying  emotional  state  and
environmental situation  in  which  the  pain  is  assessed.
Therefore,  when  pain  is  studied  between  different  indi-
viduals, from  different  regions  and  in  different  conditions
the results  are  neither  trustworthy  or  dependable  nor  con-
sistent. A  ‘‘Pain  Vision’’  system  has  been  recently  proposed
for quantitative  assessment  of  pain  caused  by  the  removal  of
adhesive wound  dressing  materials  which  takes  into  account
every patient’s  pain  threshold.20
We  believe  that  in  this  study  a  new  way  of  pain
assessment has  been  put  forward.  In  this  method,  every
individual’s hand  is  used  as  the  case  and  control  groups
for pain  perception,  therefore  reducing  or  even  eliminating
the mentioned  intervariability  in  pain  perception  and  con-
founding factors.  In  our  previous  work  in  which  we  assessed
the effect  of  dexamethasone  on  injection  pain  of  diazepam
hydrochloride,21 we  used  the  this  method  too.
It should  be  noted  that  to  our  knowledge  in  all  the  previ-
ously injection  pain  assessment  studies  the  method  used  to
assess pain  was  different  to  our  study  and  pain  on  injection
was assessed  between  different  individuals.  This  could  lead
to less  reliable  results.
We  propose  the  method  used  in  this  study  as  a  novel  and
effective way  of  assessing  injection  pain  of  various  drugs.  We
are  currently  conducting  a  series  of  clinical  trials,  using  the
1171
entioned  method,  evaluating  the  effect  of  ondansetron
nd granisetron  on  the  pain  on  injection  of  etomidate  and
ropofol.
The question  that  what  dosage  of  ondansetron  is  required
o prevent  injection  pain  of  various  drugs  remains  unan-
wered. Urticaria  which  developed  in  6  patients  was  the
egative aspect  of  ondansetron  administration,  although
his was  very  short  lasting  and  was  probably  related  to
he preservatives  used  and  no  major  complication  occurred
n any  of  the  individuals.2 It  should  also  be  noted  that
ndansetron’s antiemetic  effect  can  help  attenuate  the
ostoperative nausea  and  vomiting  effect  of  etomidate.  We
ould  not  measure  this  variable  because  all  the  patients
ere administered  ondansetron  and  we  had  no  control
roup.
In conclusion,  the  result  of  this  study  demonstrated  that
ndansetron could  effectively  reduce  pain  on  injection  of
tomidate.
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